Trial Profile
An Open-label, Single Arm, Single Center Clinical Study In Healthy Subjects to Qualify an In-house Reference Standard Batch of Sci-B-Vac
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors VBI Vaccines
- 28 Jun 2022 Last checked against ClinicalTrials.gov record.
- 26 Jun 2021 Results assessing speed to seroprotection, immunogenicity and safety of prophylactic HBV vaccine from five clinical trials: PROTECT, CONSTANT, SG-005-05, 38-13-040 and SciB018 presented at The International Liver Congress 2021
- 15 Jan 2021 Primary endpoint (Seroprotection rate achieved one month after the third immunization with Sci-B-Vac) has been met, according to a VBI Vaccines media release.